Vancomycin + Daptomycin
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Bacteremia
Conditions
Bacteremia
Trial Timeline
Jun 1, 2011 → Jan 1, 2012
NCT ID
NCT01287832About Vancomycin + Daptomycin
Vancomycin + Daptomycin is a approved stage product being developed by Merck for Bacteremia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01287832. Target conditions include Bacteremia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01287832 | Approved | Terminated |
Competing Products
9 competing products in Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin + Comparator | Merck | Approved | 85 |
| Daptomycin for Injection | Merck | Phase 2 | 52 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 77 |
| Cefazolin IV + Linezolid IV + Vancomycin (IV) | Pfizer | Phase 3 | 76 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| ceftobiprole medocaril | Basilea Pharmaceutica | Phase 2 | 47 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| AP-SA02 | Armata Pharmaceuticals | Phase 1/2 | 33 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |